Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARATIVE STUDY OF COMBINED DRUGS OF ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE: «RENIPRIL HT» AND «CO-RENITEC» IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION

https://doi.org/10.20996/1819-6446-2005-1-3-29-34

Full Text:

Abstract

Aim. Tto study efficiency and safety of new combined drug of enalapril maleate and hydrochlorothiazide “Renipril HT: in patients with mild to moderate arterial hypertension (AH) in comparison with the original combined drug with the same substances – “Co-renitec”, possibility of reaching target blood pressure (BP) level with separate treatment with each drug, and in combination with atenolol if necessary.

Material and methods. 30 patients (11 men and 19 women) with mild to moderate AH took part in randomized, open, cross over study. 10-14 days before the study started, previous antihypertensive treatment had been canceled for all the patients. Each patient by turns was treated during 6 weeks with Renipril HT (RH) and Co-renitec (CR). Efficiency of antihypertensive therapy was assessed at visits to physician every 2 weeks within the whole period of study. Within first 2 weeks patients were treated with RH 10/12,5 mg daily or CR 10/6,25 mg daily. Within next 2 weeks doses of drugs were doubled if target BP level (<140/90 mmHg) was not reached. If therapy with doubled doses of combined drugs was inefficient, atenolol 25 mg daily was added for the last 2 weeks of treatment with each drug. After 6-week treatment with the first randomized drug, antihypertensive therapy was canceled for 7-14 days depending on addition of atenolol to the therapy.

Results. After 6-week treatment with RH average level of systolic BP reduced by 21,8 mmHg compared to the initial level, after 6-week treatment with CR – by 23,8 mmHg. Average level of diastolic BP reduced by 10,8 and 13,5 mmHg respectively (differences between drugs in BP decrease are not significant). By the end of 6-week treatment with RH target BP level was reached in 74% of patients, with CR - in 64% of patients. Bigger number of side-effects was registered in treatment with RH (p=0,03), but most part of them were not severe and didn’t demand therapy correction.

Conclusion. New combined drug of enalapril maleate and hydrochlorothiazide – RH is an efficient and safe antihypertensive drug with all advantages of combined drugs. It has no less efficiency than the original drug with the same active components – CR in patients with mild to moderate hypertension. Convenience of taking – once per day – provides high compliance with treatment with this drug.

About the Authors

S. Y. Martsevich
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


J. V. Lukina
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


A. D. Deev
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


N. S. Oganisyan
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


N. A. Dmitrieva
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


N. Y. Ivanenkova
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


A. A. Serazhim
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


V. P. Voronina
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


M. P. Kozireva
State Research Center for Preventive Medicine of Roszdrav, Moscow
Russian Federation


References

1. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония в вопросах и ответах. Справочник для практикующих врачей. М., 2002, 100.

2. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Разработаны Комитетом экспертов Всероссийского научного общества кардиологов (секция артериальной гипертонии ВНОК). М., 2004. Приложение к журналу «Кардиоваскулярная терапия и профилактика».

3. Neal B., MacMahon S., Chapman N. for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 2000;355:1955-1964.

4. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension J Hypertension 2003;21:1011.

5. Messerli FH Clinican"s manual on combination therapy and hypertension SP, 2003, pp.62

6. Арутюнов Г.П., Розанов А.В. Контроль артериальной гипертонии: комбинированная терапия или фиксированная комбинация? Атмосфера. Кардиология 2003;3:10-13

7. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств.- 2-е изд., перераб. и доп. М., Изд-во “БИНОМ” – СПб.: Невский диалект, 2002:394- 397.

8. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med, 1997;157:2413

9. Е.В. Ощепкова, Л.Г. Исаева Низкая приверженность больных артериальной гипертонией к лечению: подходы к ее улучшению. Атмосфера. Кардиология 2003;3:33-36

10. Чазова И.Е., Ратова Л.Г., Дмитриев В.В. и др. Ко-Ренитек при лечении больных с умеренной и тяжелой формами гипертонической болезни. Тер. арх. 2003;8:21–26.


For citation:


Martsevich S.Y., Lukina J.V., Deev A.D., Oganisyan N.S., Dmitrieva N.A., Ivanenkova N.Y., Serazhim A.A., Voronina V.P., Kozireva M.P. COMPARATIVE STUDY OF COMBINED DRUGS OF ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE: «RENIPRIL HT» AND «CO-RENITEC» IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2005;1(3):29-34. (In Russ.) https://doi.org/10.20996/1819-6446-2005-1-3-29-34

Views: 662


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)